

+




FIG. 1




FIG. 2

+

2/60




FIG. 3

3/60




FIG. 4A

4/60




FIG. 4B

5/60

	Formulation	Dose Level (mg/kg)	C _{max} (ng/mL)	T _{max} (min)	AUC _(0-∞) (ng·hr/mL)	T _{1/2} (hr)	Volume of Distribution at Steady State (mL/kg)	Clearance Rate (mL/hr·kg)	Bioavailability (%)
Mean	Celecoxib IV	1	718	NA	3808	8.21	2498	278	NA
SD		NA	91	NA	933	2.85	590	77	NA
Mean	Celecoxib PO	5.09	654	1.25	7663	9.3	NA	798	40.05
SD		0.050	199	0.88	3119	3.48	NA	317	15.45
Mean	Celecoxib Sodium PO	5.05	2142	0.75	16426	9.0	NA	323	85.80
SD		0.121	569	0.27	4150	2.71	NA	77	7.82

FIG. 5

6/60





FIG. 6

7/60



Poloxamer	Physical form	a	b	Average molecular weight	Percent a	Percent b	Ratio a/b
124	Liquid	12	20	2090-2360	0.38	0.63	0.60
188	Solid	80	27	7680-9510	0.75	0.25	2.96
		64	37	6840-8830			1.73
338	Solid	141	44	12 700-17 400	0.76	0.24	3.20
		101	56	9840-14 600			1.80




FIG. 7

8/60

Effects of Celluloses on Dissolution of 1/1 Vitamin E TP GS/TPI-336-Na at Room Temperature




FIG. 8

Dissolution Test at 37C for Various Ratio of Vitamin E TP GS : HP-Cellulose : TPI336 Na




FIG. 9

9/60

Dissolution profile of TPI-336-Na in SGF from solid mixtures with excipients at room temperature




FIG. 10

Effect of Avicel and Silica Gel on the dissolution of TPI336Na/Vit E TPGS/HPC mixtures in SGF at 37C




FIG. 11

10/60




FIG. 12




FIG. 13

11/60




FIG. 13B

12/60

DSC




FIG. 14

13/60

TGA




FIG. 15

14/60




FIG. 16




FIG. 17

15/60

DSC




FIG. 18

16/60

TGA




FIG. 19

17/60




FIG. 20




FIG. 21

18/60

TGA




FIG. 22

19/60




FIG. 23




FIG. 24

20/60

TGA




FIG. 25

21/60




FIG. 26

22/60




FIG. 27




FIG. 28

23/60




FIG. 29

24/60




FIG. 30

25/60




FIG. 31

26/60




FIG. 32

27/60




FIG. 33

28/60




FIG. 34

29/60




FIG. 35

30/60




FIG. 36

31/60




FIG. 37

32/60




FIG. 38

33/60

TGA




FIG. 39

34/60




FIG. 40

TGA




FIG. 41

35/60




FIG. 42

36/60

TGA




FIG. 43

37/60




FIG. 44

09/38




FIG. 45

39/60




FIG. 46

09/40




FIG. 47

41/60




FIG. 48

42/60




FIG. 49

43/60




FIG. 50

44/60




FIG. 51

45/60




FIG. 52

46/60

17% RH
Celecoxib Na hydrate
Batch No. MT_138_A




FIG. 53

47/60

31% RH
Celecoxib Na hydrate
Batch No. MT_138_A




FIG. 54

48/60

59% RH

Celecoxib Na hydrate

Batch No. MT_143_25




FIG. 55

49/60

74% RH
Celecoxib Na hydrate
Batch No. MT_138_A




FIG. 56

50/60

17% RH
Celecoxib Na propylene glycol solvate
Batch No. MT_143_25




FIG. 57

51/60

31% RH

Celecoxib Na propylene glycol solvate

Batch No. MT_143_25




FIG. 58

52/60

59% RH

Celecoxib Na propylene glycol solvate

Batch No. MT_143_25




FIG. 59

53/60

74% RH

Celecoxib Na propylene glycol solvate

Batch No. MT_143_25




FIG. 60




FIG. 61

55/60

DSC




FIG. 62

TGA




FIG. 63




FIG. 64




FIG. 65

57/60




FIG. 66

58/60
DSC




FIG. 67

TGA




FIG. 68

59/60




FIG. 69




FIG. 70

60/60

EXPANDED 1H OBSERVE

exp1 std4h

SAMPLE		DEC. & VT	
date	Jul 11 2002	dfrq	299.963
solvent	DMSO	dn	H1
file	exp	dpr	26
ACQUISITION		dof	0
gfrq	299.964	dm	nm
tn	H1	dmm	c
at	2.502	dmf	200
np	30016	homo	n
sw	5998.8	dseq	1.0
fb	3400	ures	
bs	16	PROCESSING	
tpwr	59	wtfile	
pw	8.7	proc	ft
di	1.000	fn	not used
tof	735.4	math	f
nt	8		
ct	8	herr	
alock	n	wexp	
gain	not used	wbs	
FLAGS		wnt	
il	n		
in	n		
dp	y		
hs	nn		
DISPLAY			
sp	-30.3		
wp	3153.0		
vs	125		
sc	0		
wc	250		
hzmm	12.61		
is	1113.75		
rfl	764.1		
rfp	0		
th	20		
ins	100.000		
nm	ph		




FIG. 71